Clinical Trial Update: PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression [Phase 2]

View source ↗

Summary

Phase 2 pilot study assessing personalized antibodies for metastatic gastro-esophageal adenocarcinoma (biologics beyond progression).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Gastroesophageal Adenocarcinoma

Snippet

Sponsor: University of Chicago | Conditions: Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-04-08